tbuckley/cabot-search huggingface dataset:
The Common Diseases of the Skin: A Handbook for Students and Medical Practitioners
Authors: Robert Cranston Low, George Alexander Grant Peterkin
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase
Authors: CR Calabrese, NJ Curtin, SS Canan-Koch, MA Batey, HD Thomas, S Kyle, LZ Wang, TJ Boritzki, SE Webber, RJ Griffin, BT Golding, Z Hostomsky, AH Calvert, Newell
Journal: Clinical Cancer Research (2000)
Abstract 1003: Nitric Oxide-Dependent Phosphorylation of Vasodilator-Stimulated Phosphoprotein Regulates Vascular Smooth Muscle Cell Contraction, Adhesion and Spreading
Authors: Olivier D Defawe, Lihua Chen, Daming Huang, Constanze Blume, Ulrich Walter, Gunter Daum, Alexander W Clowes
Journal: Circulation (2006)
Selective Targeting Of Inv(16)+ AML Stem Progenitor Cells By Inhibiting HDAC8
Authors: Jing Qi, Sandeep Singh, Qi Cai, Ling Li, Hongjun Liu, Hieu Vu, wei-Jan Huang, Tinisha McDonald, Allen Lin, chung-I Chang, Ravi Bhatia, Ya-Huei Kuo
Journal: Blood (2013)
Bevacizumab (BEV) and continuous low-dose granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid tumors: final results of a prospective clinical trial
Authors: C. M. Kurbacher, M. Schmidt, J. A. Kurbacher, S. Schäfer, P. N. Arenz, W. J. Nagel, U. Reinhold
Journal: Journal of Clinical Oncology (2009)

e14544 Background: BEV is potent inhibitor of VEGF-mediated tumor angiogenesis. VEGF is also crucial in antineoplastic immunortolerance by blocking the generation of dendritic cells (DC). VEGF inhibition may thus result in an improved anti-cancer immune response which may be further augmented by GM-CSF, a powerful stimulator of DC generation. In a previous study, GM-CSF was able to produce clinical responses in patients (pts) suffering from refractory carcinomas (Kurbacher et al., Oncology 2005). In this trial, we investigated BEV+GM-CSF in pts with advanced solid neoplasms. Methods: 26 pts have been enrolled: epithelial ovarian cancer, n=12; breast cancer, n= 6; primary peritoneal carcinoma, n=3; hormone-refractory prostate cancer, n=2; miscellaneous, n=3. All pts have been considered refractory to or non-treatable by chemotherapy due to their baseline bone marrow and/or organ functions. Fourteen pts had previously received BEV as part of other antineoplastic regimens. BEV was applied at a fixed dose of 6 mg/kg q2w. The starting dose of GM-CSF (sargramostim) was 125 μg/d. In cases not responding and/or not achieving moderate leukocytosis (&lt; 20 G/L), GM-CSF was increased every 4 weeks at 25 μg increments up to a maximum of 250 μg/d. Toxicity was documented according to the NCI-CTC score, responses were recorded according to the RECIST or Rustin criteria. Results: Grade (G) 3–4 hypertension was seen in 3 pts, with 1 pt experiencing cerebral stroke 6 weeks after cessation of BEV+GM-CSF. Other G3–4 toxicities were fatigue in two pts, and fever, pain, myalgia, and central nervous symptoms in either one pt. Other side-effects like injection-site reactions, proteinuria, anemia, thrombocytopenia, and constipation did not exceed G1–2. The objective response rate was 31% (1 CR, 7 PR, 10 SD, and 8 PD); the rate of pts benefiting was 69%. Eight pts failing prior BEV benefited from BEV+GM-CSF. Until today, 13 pts have died. The median time to progression is 92 days and the median overall survival is 302 days. Conclusions: BEV+GM-CSF is an active and generally well tolerated non-cytotoxic regimen in pts with advanced solid tumors. Thus, large-scaled studies of this promising treatment are warranted. No significant financial relationships to disclose.
Diagnostic accuracy of quantitative stress echocardiography using tissue Doppler. Final results of the MYDISE study.
Authors: CF Madler, N Payne, RG Newcombe, G Derumeaux, L Pierard, J Engvall, GR Sutherland, LA Brodin, AG Fraser
Journal: Circulation (2001)

Diagnostic accuracy of quantitative stress echocardiography using tissue Doppler. Final results of the MYDISE study.
Clinical Transesophageal Echocardiography
Authors: Howard C. Dittrich
Journal: Annals of Internal Medicine (1992)

A practical introduction to the use of transoesophageal echocardiography (TE) in the diagnosis of cardiac and cardiovascular disease. It provides complete information for performing and interpreting TE echo studies. The book is divided into four parts: technical aspects including the basics of TE in awake patients, techniques, normal anatomy, and image planes, and problems and pitfalls; clinical applications - including diagrams or evaluation of emboli, problems with native and prosthetic valves, tumours, aortic disease and congenital heart disease; applications in surgery and intensive care - including how to perform standard echo and TE intraoperatively, TE for intraoperative monitoring and uses in critically ill patients; and new and future technology. Extensive illustrations provide anatomical insight.
De Venarum Ostiolis 1603 of Hieronymus Fabricius of Aquapendente
Authors: Fabricius, ab Aquapendente, ca., Kenneth J. Franklin
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection of promoter hypermethylation of RARβ, RASSF1A, DAPK and P16/ INK4a genes in cell-free DNA from serum (s) and pleural liquid (pl) of patients (p) with pleural effusion
Authors: B. Massuti, S. Benlloch, J. Sanchez-Paya, J. J. Mafe, B. Baschwitz, C. Fernandez, J. L. Ramirez, J. L. Marti-Ciriquian, J. Galbis
Journal: Journal of Clinical Oncology (2005)

9637 Background: Aberrant gene promoter methylation (AM) is a major mechanism for tumour suppressor gene (TSG) silencing in all tumour types and affects their development and aggressiveness.AM of RARβ,RASSF1A, DAPK,P16/INK4a genes have shown to be involved in most tumors. Objectives: 1) to assess the concordance of gene promoter hypermethylation in paired s and pl samples of cancer p with malignant pleural effusion 2) to investigate their role as a marker of pleural effusion malignancy. Methods: We evaluated 53 consecutive p presenting pleural effusion and malignancy(24 lung,11 digestive,8 breast,4 ovary,6 others) at the General Hospital of Alicante (Spain).Hypermethylation of TSG were investigated by using methylation-specific PCR(MSP)after sodium bisulphite treatment. Results: Conventional cytology of pleural effusion samples revealed neoplastic cells in 17 of 48 p (35,5%). AM of at least one of the genes tested was detected in 24 out of 53 p (45,3%) in s and in 31 out of 53 p (58,6%) in pl. In pl 34% had only 1 gene methylated,17, 0% had 2 genes methylated, 5,7% had 3 genes methylated and only 1,9% had 4 genes methylated. In s,14% had only 1 gene methylated,8% had 2 genes methylated and only 2% had 3 genes methylated. Concordance in the pattern of aberrant methylation was found in paired s and pl samples of 13 p. In 11 p, methylation was found only in pl and not in s; only in 3 patients was found in serum and not in pleural liquid. AM of DAPK was found in 7 p (13,2%) in s and 10 p (18,9%) in pl; in 10 p (18,9%) in s and 20 p (37,7%) in pl for P16/INK4a; in 9 p (17%) in s and 8 p (15,1%) in pl for RASSF1A and in 10 p (18,9%) in s and 11 p (20,8%) in pl for RARβ. Correlation coefficient between s and pl methylated genes was r=0,6 p<,0001. Median survival time of p with at least one gene methylated in pl was 12,63±5,95 mo; for p with none of genes methylated median survival has not yet reached. Conclusions: 1) Aberrant gene promoter methylation of TSG can be detected in pleural liquid 2) In pleural liquid, 58,6% of p were found to have at least one TSG methylated vs 35,5% of p with neoplastic cells by conventional cytology 3) Aberrant methylation showed a negative prognostic effect. No significant financial relationships to disclose.
The Sanitation of Water Supplies.
Authors: Murray P. Horwood
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
床旁D-二聚体检测在门诊患者排除静脉血栓栓塞的价值：一项诊断性荟萃分析
Authors: Geersing, Oudega, Bax, Hoes, Reitsma, 高晓方, 陈良安, 何耀
Journal: BMJ (2009)

目的对目前排除静脉血栓栓塞的床旁D-二聚体检测的诊断准确性的证据进行评价。设计利用双变量回归检验变异来源，系统评价关于床旁D-二聚体检测的准确性的相关研究，并对敏感性和特异性进行评估。数据来源发表于1995年1月至2008年9月，并且于Medline和Embase中可检索到的关于床旁D-二聚体检测的诊断准确性的研究报告。评价方法纳入荟萃分析的研究需满足如下条件：对床旁D-二聚体检测与预先定义的静脉血栓栓塞的D-二聚体参考标准进行比较，人选患者为连续门诊病例，并且能够以此构建2×2表格。结果共有23项研究报告（病例总数为13959例，平均年龄为38—65岁，静脉血栓栓塞发病率为4％～51％）纳入荟萃分析。这些研究报告了两种床旁D-二聚体定性检测方法（SimpliREDD-二聚体（n=12）和Clearview Simplify D-二聚体（n=7））和两种床旁D-二聚体定量检测方法（CardiacD-二聚体（n=4）和Triage D-二聚体（n=2））。总体敏感性处于0．85（95％可信区间为0．78～0．90）至0．96（0．91～0．98）之间；总体特异性处于0．48（0．33～0．62）至0．74（0．96～0．78）之间。CardiacD-二聚体和TriageD-二聚体这两种定量检测方法评分最佳。结论在可疑静脉血栓栓塞的门诊患者中，床旁D-二聚体检测能够提供重要信息并指导治疗，在低风险患者（即临床决策规则评分较低的患者）中的价值尤为显著。
Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia
Authors: Farhad Ravandi, Susan O'Brien, Rebecca Garris, Stefan H. Faderl, Deborah A. Thomas, Jan A. Burger, Alessandra Ferrajoli, Elias Jabbour, Jorge E. Cortes, Hagop M. Kantarjian
Journal: Blood (2013)
Predictive validity of judgments of dangerousness in emergency civil commitment
Authors: D E McNiel, R L Binder
Journal: American Journal of Psychiatry (1987)

The authors investigated the predictive validity of judgments of dangerousness made in the context of emergency civil commitment. The medical charts of 101 consecutive patients involuntarily admitted to a university-based acute inpatient unit were reviewed for evidence of violence within the first 72 hours of hospitalization. More than two-thirds of the patients committed as a danger to others engaged in some type of violence, compared with fewer than one-third of other involuntary patients. The findings suggest that the emergency commitment situation permits judgments of dangerousness with a relatively high degree of short-term predictive validity.
Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)
Authors: Stephen P. Mulligan, Devinder Gill, Paul Turner, William E. P. Renwick, Maya Latimer, Naomi Mackinlay, Leanne Berkahn, David R Simpson, Philip Campbell, Cecily J Forsyth, Gavin Cull, Rosemary Harrup, Melanie Sulda, Giles Best, Mathias Bressel, Juliana Di Iulio, Bryone J Kuss
Journal: Blood (2014)
Should oral contraceptive users be screened for factor V Leiden?
Authors: T. Ward, J P Vandenbroucke
Journal: BMJ (1997)

In their paper on the prospect of screening potential  contraceptive users for the thrombogenic variant factor V Leiden Jan P. Vandenbroucke and colleagues conclude that such a strategy would  effective  to about 5% of White women while preventing only a small number of fatal pulmonary emboli.  Their persistent use of the term oral contraceptives fails to distinguish clearly between progesterone-only and combined  contraceptive preparations which have quite different thrombogenic risk profiles.  Furthermore the authors imply that   is the only effective contraception.  This is both erroneous and unhelpful.  While screening for factor V Leiden might deny 5% of White women the opportunity of using the combined pill it does not necessarily preclude them from using depot or  progesterone intrauterine devices or barrier methods all of which are effective in appropriate circumstances.  The authors comment about the related strain due to unappealing methods of contraception reflects personal prejudice not scientific fact.  (full text)
Optic and chiasm tumors: present perspectives in diagnosis and treatment
Authors: R. M. Villani, G. Miserocchi, S. Balbi, M. Caroli, M. Egidi, S. M. Gaini, G. Tomei
Journal: Neuro-Oncology (1991)

During the period 1950–1990, 67 cases of anterior optic pathways gliomas have been observed in our Institute (48 were in the paediatric age). During the last decade, CT and MRI have greatly improved the diagnostic capabilities allowing a more precise definition of the tumor size and site and involvement of the contiguous structures. Options in the treatment should vary according to the different anatomical situations. Surgical resection is indicated for tumors involving a single optic nerve when visual functions are completely compromised. In these cases long-term results are excellent. In optic nerve cases with preserved visual functions, a clinical, neuroradiological and neurophysiological (PEV) monitoring is mandatory and no therapy should be adopted. When involvement of both optic nerve and chiasm is demonstrated, surgery is indicated only in the presence of particular conditions:well delimited cystic lesions or exophitic growths. When the tumor infiltrates the hypothalamic region and in the cases in which only a biopsy is possible, radiotherapy should be adopted.
Abstract P2-06-08: SIRT1 inhibitors significantly reduce cancer stem cells and block epithelial mesenchymal transformation in breast cancer cells
Authors: Songlin Zhang, Min Li, Baoxiang Guan, Robert Brown
Journal: Cancer Research (2015)

Abstract Breast cancer stem cells are contribute to distance metastasis, breast cancer recurrence and drug resistance. SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylase, play significant role in DNA repair, cell survival, stem cells and epigenetic modification. SIRT1 has been related to cancer stem cells in chronic myelogenous leukemia. In this study, we investigate the role of SIRT1 in breast cancer stem cells. SIRT1 inhibitors cambinol and Ex527 are used for treatment in several breast cancer cell lines, including T47D, TB549, MDA-MB-231 and MDA-MB-468. Stem cell markers, SOX-2 and Nanog, are significantly decreased in SIRT1 inhibitor treated cancer cells by qRT-PCR and western blot in T47D cell line. The ALDH positive cells in MDA-MB-231 cell line are significant reduced from 29% to 3.2% with Adeflour assay, and the CD44 expression is significantly reduced in CD44/CD24 flow cytometry analysis. Using qRT-PCR, SIRT1 inhibitors significantly down regulate vimentin (-3.7 folds), N-cadherin and smooth muscle actin (-2.7 folds) and up regulate the gene of E-cadherin, indicating SIRT1 inhibitors can block the epithelial mesenchymal transformation (EMT) of breast cancer. SIRT1 inhibitors can significantly (40-50%) block the cancer cell invasion and migration in several triple negative breast cancer cell lines. SIRT1 inhibitors can inhibit cell proliferation on all tested breast cancer cell lines, and can induce significant cell apoptosis in T47D cells. In xenograft tumor study, SIRT1 inhibitor cambinol can significantly reduce tumor growth and inhibit tumor metastasis. The molecular mechanism of SIRT1 inhibitors in blocking EMT and reducing cancer stem cells is likely associated with blocking the Wnt pathway. Several down stream target genes of Wnt pathway, such as cyclin D1, c-Myc and c-Jun, are significantly down regulated after using SIRT1 inhibitor cambinol, and the changes are more significant in TGF-beta stimulated cancer cells. Beta-catenin is significantly reduced including the active beta-catenin, and the decreasing beta-catenin protein may be related to the decreased Dvl proteins. In summary, our study demonstrated that SIRT1 inhibitors can reduce breast cancer stem cell population in several cancer cell lines, block epithelial mesenchymal transformation, and inhibit breast cancer cell invasion and metastasis. SIRT1 inhibitors appear to inhibit Wnt pathway in cancer cells to block EMT and affect cancer stem cells. Citation Format: Songlin Zhang, Min Li, Baoxiang Guan, Robert Brown. SIRT1 inhibitors significantly reduce cancer stem cells and block epithelial mesenchymal transformation in breast cancer cells [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-06-08.
Clonazepam treatment of five lithium-refractory patients with bipolar disorder
Authors: T A Aronson, S Shukla, J Hirschowitz
Journal: American Journal of Psychiatry (1989)

The authors describe the first five patients enrolled in an open clinical trial of clonazepam as a maintenance treatment in lithium-refractory bipolar disorder. All patients relapsed quickly after taking clonazepam (one within 2 weeks and four within 10-15 weeks), and the study was prematurely terminated. The results cast doubt over the usefulness of clonazepam as a prophylaxis in lithium-resistant bipolar patients who have histories of psychotic mania or delusional depression.
The Microbiology and Microanalysis of Foods.
Authors: Albert Schneider
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1138: Endogenous Adipocyte-Derived Factors Diminish Coronary Endothelial-Dependent Vasodilation Via Inhibition Of Nitric Oxide Synthase
Authors: Gregory A Payne, Lena Borbouse, Gregory M Dick, Johnathan D Tune
Journal: Circulation (2007)

Adipocytokines may be the molecular link between obesity and vascular disease; however, effects of these factors on coronary vascular function have not been delineated. Accordingly, this study was designed to examine mechanisms by which endogenous adipocyte-derived factors impair coronary endothelial-dependent vasodilation in vivo . Experiments were conducted in open-chest anesthetized dogs (n = 16) before and during treatment with endogenous adipocyte-derived factors. Phosphate buffered saline was conditioned in a shaking water bath with parietal pericardial adipose tissue (3 g/ml) for 30 min at 37°C. The conditioned buffer was then filtered (0.2 μm) and infused directly into the coronary circulation (0.3 ml/min). Conditioned buffer did not significantly affect baseline coronary blood flow (0.50 ± 0.01 vs. 0.61 ± 0.05 ml/min/g, p = 0.68), mean arterial pressure (103 ± 6 vs. 96 ± 9 mmHg, p = 0.74), or heart rate (87 ± 13 vs. 110 ± 24 beats/min, p = 0.44). Conditioned buffer had no effect on responses to intracoronary angiotensin II (2.5 – 750 ng; 74 vs. 70% vasoconstriction). Under control conditions, bradykinin (0.03 – 3 μg/min) increased coronary blood flow (303 ± 65%) to 2.02 ± 0.31 ml/min/g in a dose-dependent manner. Conditioned buffer attenuated maximum bradykinin vasodilation to 1.64 ± 0.26 ml/min/g (167 ± 33% increase; p &lt; 0.05). This decrease in endothelial-dependent dilation was not due to increases in superoxide production, as administration of the superoxide dismutase mimetic Tempol (10 mg/min, ic) did not improve bradykinin vasodilation (120 ± 27% increase; p &lt; 0.05). Inhibition of nitric oxide synthase with L-NAME (150 μg/min, ic) reduced maximum bradykinin vasodilation to 0.93 ± 0.04 ml/min/g (p &lt; 0.05) and endogenous adipocyte-derived factors had no further inhibitory effect (0.82 ± 0.09 ml/min/g, p = 0.24). These data indicate that endogenous adipocyte-derived factors diminish endothelial-dependent coronary vasodilation via inhibition of nitric oxide synthase rather than a reduction in nitric oxide bioavailability by superoxide. Our findings importantly link endogenous adipocyte-derived factors with pro-atherogenic coronary vascular dysfunction in vivo .